News
3 major takeaways from Novo Nordisk's Q1 earnings
Novo Nordisk (NVO) topped first quarter earnings estimates while its revenue figures came in line with analyst expectations Yahoo Finance senior health reporter Anjalee Khemlani joins the Catlaysts team to share the biggest takeaways from the pharmaceutical giant's earnings,
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Despite last ...
The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...
Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug ...
The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...
Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...
Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions ...
1d
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
Novo Nordisk A/S shares gained on expectations that competition for its blockbuster obesity shot Wegovy will subside later ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback